These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 23027046)
41. RNA interference (RNAi) in hematology. Scherr M; Steinmann D; Eder M Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462 [TBL] [Abstract][Full Text] [Related]
42. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. DeVincenzo JP Antivir Ther; 2012; 17(1 Pt B):213-25. PubMed ID: 22311654 [TBL] [Abstract][Full Text] [Related]
43. The design, selection, and evaluation of highly specific and functional siRNA incorporating unlocked nucleobase analogs. Vaish N; Agarwal P Methods Mol Biol; 2013; 942():111-34. PubMed ID: 23027048 [TBL] [Abstract][Full Text] [Related]
44. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Chang LJ; Liu X; He J Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613 [TBL] [Abstract][Full Text] [Related]
45. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials. DeVincenzo JP Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462 [TBL] [Abstract][Full Text] [Related]
46. Local RNA target structure influences siRNA efficacy: a systematic global analysis. Overhoff M; Alken M; Far RK; Lemaitre M; Lebleu B; Sczakiel G; Robbins I J Mol Biol; 2005 May; 348(4):871-81. PubMed ID: 15843019 [TBL] [Abstract][Full Text] [Related]
47. A novel program to design siRNAs simultaneously effective to highly variable virus genomes. Lee HS; Ahn J; Jun EJ; Yang S; Joo CH; Kim YK; Lee H Biochem Biophys Res Commun; 2009 Jul; 384(4):431-5. PubMed ID: 19422797 [TBL] [Abstract][Full Text] [Related]
48. A novel in vitro transcription method for producing siRNAs without specific sequence requirements. Zhu X; Li T; Dang Y; Feng Y; Huang P Mol Biotechnol; 2005 Nov; 31(3):187-92. PubMed ID: 16230768 [TBL] [Abstract][Full Text] [Related]
49. What parameters to consider and which software tools to use for target selection and molecular design of small interfering RNAs. Matveeva O Methods Mol Biol; 2013; 942():1-16. PubMed ID: 23027043 [TBL] [Abstract][Full Text] [Related]
51. Methods for selecting effective siRNA target sequences using a variety of statistical and analytical techniques. Takasaki S Methods Mol Biol; 2013; 942():17-55. PubMed ID: 23027044 [TBL] [Abstract][Full Text] [Related]
53. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. Beale G; Hollins AJ; Benboubetra M; Sohail M; Fox SP; Benter I; Akhtar S J Drug Target; 2003 Aug; 11(7):449-56. PubMed ID: 15203934 [TBL] [Abstract][Full Text] [Related]
58. Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era. Wada K; Wada Y; Iwasaki Y; Ikemura T Gene Ther; 2017 Oct; 24(10):668-673. PubMed ID: 28905886 [TBL] [Abstract][Full Text] [Related]